| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Aug 19, 2024 | Sustainable Agriculture: The Growing Need for Biotech Innovations in the World's Food Supplies | USA News Group Commentary
Issued on behalf of BioVaxys Technology Corp.
VANCOUVER, BC, Aug. 19, 2024 /PRNewswire/ -- USA News Group – How we take care of the planet, and the food we eat is rapidly shifting. Back in May, the World Economic F... |
| Jul 29, 2024 | Biovaxys Signs Binding Letter of Intent to Develop DPX™-Based Vaccines for Life Threatening Food Allergies | VANCOUVER, BC, July 29, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical-stage biopharmaceutical company developing a portfolio of immune-educ... |
| Jul 26, 2024 | BioVaxys and Innovent: Pioneering New Frontiers in Immunotherapy and Diabetes Treatment**
** | ** In the ever-evolving landscape of biopharmaceuticals, two companies are making waves: BioVaxys Technology Corp. and Innovent Biologics. Each is tackling significant health challenges with innovative approaches. BioVaxys is focused on imm... |
| Jul 26, 2024 | BioVaxys and American Skin Association: Pioneering Paths in Medical Research**
** | ** In the ever-evolving landscape of medical research, two organizations stand out: BioVaxys Technology Corp. and the American Skin Association (ASA). Each is carving a niche in their respective fields, focusing on innovative solutions for ... |
| Jul 23, 2024 | BIOVAXYS ANNOUNCES ISSUANCE OF DPX RELATED PATENT FROM THE U.S. PATENT AND TRADEMARK OFFICE | VANCOUVER, BC, July 23, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announced that the United States Patent and Trademark Office ("USPTO") has ... |
| Jul 18, 2024 | Brittany Davison, CPA, CA, Joins BioVaxys as Business Advisor | VANCOUVER, BC, July 18, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") is pleased to announce that it has engaged Brittany Davison, CPA, CA as Business Advisor. Ms. Davison is ... |
| Jul 17, 2024 | BIOVAXYS AND SPAYVAC-FOR-WILDLIFE, INC. ANNOUNCE LAUNCH OF TRIAL TO TEST IMMUNOCONTRACEPTION IN ASIAN ELEPHANTS | VANCOUVER, BC and MADISON, Wis., July 17, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys") and SpayVac-for-Wildlife, Inc. ("SpayVac") jointly announce that SpayVac has par... |
| Feb 13, 2024 | BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Former IMV Inc. | VANCOUVER, BC, Feb. 13, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announced that it has executed the definitive Asset Purchase Agreement dated February... |
| Aug 26, 2022 | BIOVAXYS CLOSES FIRST TRANCHE OF NON-BROKERED PRIVATE PLACEMENT | VANCOUVER, BC, Aug. 26, 2022 /PRNewswire/ -- BioVaxys Technology Corp. BIOV 5LB BVAXF ("BioVaxys" or the "Company") is pleased to announce that it has closed the first tranche ("Tranche 1") of its previously an... |
| Jun 15, 2022 | Clinical Study Collaborator HCL Sends First Surgically Excised Ovarian Cancer Tumors to BioVaxys for BVX-0918 Vaccine Process Development | VANCOUVER, BC, June 15, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that its clinical study collaborator Hospices Civils de Lyon in Fran... |
| May 18, 2022 | BioVaxys Confirms First Clinical Site and Principal Investigators for Ovarian Cancer Vaccine Trial and Enters into Second Tumor Cell Supply Agreement | VANCOUVER, BC, May 18, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV; FRA: 5LB; OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that Hospices Civils de Lyon, France ("HCL") has agreed to se... |
| Feb 16, 2022 | BIOVAXYS ANNOUNCES complete inhibition of ACE-2 binding activity of hapten-modified SARS-CoV-2 protein | SUGGESTS superior cardiAC safety compared to mRNA AND ADENOVIRUS VECTOR vaccines
VANCOUVER, BC, Feb. 16, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAX) ("BioVaxys" or "Company") annou... |
| Feb 10, 2022 | BIOVAXYS CLOSES FIRST TRANCHE OF NON-BROKERED PRIVATE PLACEMENT | VANCOUVER, BC, Feb. 10, 2022 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") is pleased to announce that it has closed the first tranche ("Tranche 1") of i... |
| Feb 8, 2022 | BIOVAXYS ANNOUNCES NON-BROKERED PRIVATE PLACEMENT | VANCOUVER, BC, Feb. 8, 2022 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV), (FRA: 5LB), (OTCQB: BVAXF) ("BioVaxys" or the "Company") is pleased to announce a non-brokered private placement (the "Private Placement&qu... |
| Feb 8, 2022 | BIOVAXYS ANNOUNCES NON-BROKERED PRIVATE PLACEMENT | VANCOUVER, BC, Feb. 8, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV), (FRA: 5LB), (OTCQB: BVAXF) ("BioVaxys" or the "Company") is pleased to announce a non-brokered private placement (the "Private Place... |
| Feb 8, 2022 | BIOVAXYS ANNOUNCES NON-BROKERED PRIVATE PLACEMENT | VANCOUVER, BC, Feb. 8, 2022 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV), (FRA: 5LB), (OTCQB: BVAXF) ("BioVaxys" or the "Company") is pleased to announce a non-brokered private placement (the "Private Placement&qu... |
| Dec 7, 2021 | Biovaxys Announces Major Research Collaboration With The Ohio State University To Develop Broadly Reactive Pan-Sarbecovirus Vaccine | VANCOUVER, BC, Dec. 7, 2021 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company"), a clinical-stage immunotherapy company developing novel approaches to harness T cells to tre... |
| Oct 28, 2021 | BioVaxys Further Expands Intellectual Property Portfolio in Global Markets | - Files Applications for International Patent and Trademark Protection of CoviDTH
VANCOUVER, BC, Oct. 28, 2021 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV), (FRA: 5LB), (OTCQB: BVAXF) ("BioVaxys" or "Company"), announc... |
| Oct 28, 2021 | BioVaxys Further Expands Intellectual Property Portfolio in Global Markets | - Files Applications for International Patent and Trademark Protection of CoviDTH
VANCOUVER, BC, Oct. 28, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV), (FRA: 5LB), (OTCQB: BVAXF) ("BioVaxys" or "Company"), ... |
| Oct 28, 2021 | BioVaxys Further Expands Intellectual Property Portfolio in Global Markets | - Files Applications for International Patent and Trademark Protection of CoviDTH
VANCOUVER, BC, Oct. 28, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV), (FRA: 5LB), (OTCQB: BVAXF) ("BioVaxys" or "Company"), ... |
| Oct 20, 2021 | BioVaxys Files US Patent Application for Pan-Sarbecovirus Vaccine | VANCOUVER, BC, Oct. 20, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV), (FRA:5LB), (OTCQB:BVAXF) ("BioVaxys" or "Company"), announced today that it has filed with the United States Patent & Trademark Offi... |
| Sep 28, 2021 | BioVaxys Begins Toxicity Study Ahead of CoviDTH IND Submission | VANCOUVER, BC, Sept. 28, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that it has started its planned in vivo animal toxicology study of ... |
| Sep 23, 2021 | BioVaxys Prepares for Groundbreaking Study on reduced ACE2 binding capabilities of Hapten-modified SARS-CoV-2 proteins | - Potential for superior tolerability to mRNA and Adenovirus Vector vaccines
- Production Agreement signed with Millipore-Sigma for SARS-CoV-2 Vaccine Supply
VANCOUVER, BC, Sept. 23, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV... |
| Sep 20, 2021 | BioVaxys Technology : Engages Life Sciences Public Relations and Market Communications Firm 6 Degrees | VANCOUVER, British Columbia, Sept. 20, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys") announced today that it has engaged life sciences and healthcare communications firm 6 Degree... |
| Sep 17, 2021 | BioVaxys Cancer Vaccine Manufacturing Partner Bio Elpida Reaches Bioproduction Milestone | VANCOUVER, British Columbia, Sept. 17, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys"), announced today that cancer vaccine manufacturing partner Bio Elpida in Lyon, France, has re... |
| Sep 14, 2021 | BioVaxys Bioproduction Partner WuXi Biologics Completes Synthesis Of Recombinant SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH Programs | VANCOUVER, BC, Sept. 14, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys"), announced today that global CDMO partner WuXi Biologics, has completed the synthesis of recombinant SARS-C... |
| Sep 7, 2021 | Further Study in humans shows that the DTH response, the basis for CoviDTH, is highly durable and persists for at least one year after COVID-19 exposure or vaccine administration | VANCOUVER, BC and SAN CRISTÓBAL DE LA LAGUNA, Spain, Sept. 7, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "the Company") is pleased to announce that the Scientific ... |
| Aug 3, 2021 | Clinical Trial Affirms CoviDTH Diagnostic Approach to screen for T cell-mediated immune response to SARS-CoV-2 is safe and effective in humans | Yvelise Barrios, MD, PhD, Immunologist and leading expert in the clinical use of delayed type hypersensitivity ("DTH"), the mechanism behind CoviDTH, joins BioVaxys as scientific adviser
VANCOUVER, BC and SAN CRISTÓBAL DE LA LAGUN... |
| Jul 29, 2021 | BioVaxys Technology : Closes Final Tranche Of Non-Brokered Private Placement | VANCOUVER, BC, July 28, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTCQB:BVAXF) ("BioVaxys" or the "Company") is pleased to announce that it has closed the second and final tranche of its previou... |
| Jul 28, 2021 | BioVaxys Closes Final Tranche Of Non-Brokered Private Placement | |
| Jul 22, 2021 | FDA Provides Necessary Guidance For BioVaxys To Begin Preparation Of Ind For Phase I/II Clinical Trials Of CoviDTH | VANCOUVER, British Columbia, July 22, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA:5LB) (OTCQB: BVAXF) ("BioVaxys"), is pleased to announce today that the US Food and Drug Administration ("FDA") has pr... |
| Jul 15, 2021 | BioVaxys Technology : Closes First Tranche Of Non-brokered Private Placement | VANCOUVER, British Columbia, July 14, 2021 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTCQB: BVAXF) ("BioVaxys" or the "Company") is pleased to announce that it has closed the first tranche ("Tranche 1&... |
| Jun 29, 2021 | BioVaxys Technology : Announces Non-Brokered Private Placement | VANCOUVER, BC, June 28, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTCQB:BVAXF) ("BioVaxys" or the "Company") is pleased to announce a non-brokered private placement (the "Private Placement&... |
| Jun 29, 2021 | BioVaxys Announces Non-Brokered Private Placement | VANCOUVER, BC, June 29, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTCQB:BVAXF) ("BioVaxys" or the "Company") is pleased to announce a non-brokered private placement (the "Private Placement&... |
| Jun 28, 2021 | BioVaxys Announces Non-Brokered Private Placement | |
| Jun 15, 2021 | BioVaxys Receives Positive FDA Response For Pre-IND Review For CoviDTH Clinical Development | VANCOUVER, British Columbia, June 15, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys"), is pleased to announce today that the US Food and Drug Administration (FDA) has reviewed its ... |
| Jun 14, 2021 | BIOVAXYS TECHNOLOGY CORP.
BioVaxys Technology : Receives Positive FDA Response For Pre-IND Review For CoviDTH Clinical Development | VANCOUVER, British Columbia, June 14, 2021 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys"), is pleased to announce today that the US Food and Drug Administration (FDA) has reviewed its Pre-IND... |
| Jun 14, 2021 | BioVaxys Receives Positive FDA Response For Pre-IND Review For CoviDTH Clinical Development | |
| Jun 1, 2021 | BioVaxys And Bioproduction Partner Bio Elpida Begin Construction Of GMP Facility To Produce Clinical Supply For Planned Ovarian Cancer Vaccine Study | VANCOUVER, BC and LYON, France, June 1, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (US OTCQB: BVAXF) ("BioVaxys" or "the Company") is pleased to announce that its bioproduction partner Bio Elpi... |
| May 24, 2021 | Biovaxys Strengthens Internal Expertise With Appointment Of Scientific Advisor For Ovarian Cancer Vaccine Clinical Program And Papilocare Marketing | VANCOUVER, British Columbia, May 24, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB, US OTCQB: BVAXF) ("BioVaxys" or "the Company") is pleased to announce that Charles J. Dunton, MD, has joined BioVa... |
| May 20, 2021 | BioVaxys Announces Appointment of Policy Advisor | VANCOUVER, BC, May 20, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA:5LB) (OTC:BVAXF) ("BioVaxys"), a biotechnology company that is advancing viral and oncology vaccine platforms as well as immuno-diagnostic prod... |
| May 20, 2021 | BioVaxys Announces Appointment of Policy Advisor
USA - English España - español | |
| May 20, 2021 | BIOVAXYS TECHNOLOGY CORP.
BioVaxys Technology : Announces Appointment of Policy Advisor | VANCOUVER, BC, May 20, 2021 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA:5LB) (OTC:BVAXF) ("BioVaxys"), a biotechnology company that is advancing viral and oncology vaccine platforms as well as immuno-diagnostic products, t... |
| May 19, 2021 | BioVaxys Announces Uplisting To The OCTQB Venture Market | |
| May 19, 2021 | BIOVAXYS TECHNOLOGY CORP.
BioVaxys Technology : Announces Uplisting To The OCTQB Venture Market | VANCOUVER, BC, May 19, 2021 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV), (FRA: 5LB), (OTCQB: BVAXF) ("BioVaxys"), the world leader in haptenized antigen vaccines for antiviral and cancer applications, is pleased to announce tha... |
| May 19, 2021 | BioVaxys Announces Uplisting To The OCTQB Venture Market | VANCOUVER, BC, May 19, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV), (FRA: 5LB), (OTCQB: BVAXF) ("BioVaxys"), the world leader in haptenized antigen vaccines for antiviral and cancer applications, is pleased to annou... |
| May 19, 2021 | BioVaxys Announces Uplisting To The OCTQB Venture Market | VANCOUVER, BC, May 19, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV), (FRA:5LB), (OTCQB:BVAXF) ("BioVaxys"), the world leader in haptenized antigen vaccines for antiviral and cancer applications, is pleased to announc... |
| May 19, 2021 | BioVaxys Announces Uplisting To The OCTQB Venture Market | VANCOUVER, BC, May 19, 2021 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV), (FRA: 5LB), (OTCQB: BVAXF) ("BioVaxys"), the world leader in haptenized antigen vaccines for antiviral and cancer applications, is pleased to announce tha... |
| May 3, 2021 | BioVaxys And BioElpida Sign Definitive Exclusive Agreement To Begin Ovarian Cancer Vaccine Bioproduction | VANCOUVER, BC, May 3, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (CSE: BIOV.CN) (FRA: 5LB) (OTC: BVAXF) ("BioVaxys" or "Company") announced today that it has signed the definitive exclusive bioproduction ... |
| May 3, 2021 | BIOVAXYS TECHNOLOGY CORP.
BioVaxys Technology : And BioElpida Sign Definitive Exclusive Agreement To Begin Ovarian Cancer Vaccine Bioproduction | VANCOUVER, BC, May 3, 2021 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (CSE: BIOV.CN) (FRA: 5LB) (OTC: BVAXF) ("BioVaxys" or "Company") announced today that it has signed the definitive exclusive bioproduction agreeme... |
| May 3, 2021 | BioVaxys And BioElpida Sign Definitive Exclusive Agreement To Begin Ovarian Cancer Vaccine Bioproduction | |
| Apr 20, 2021 | Biovaxys And The World Ovarian Cancer Coalition Join Forces For May 8th, World Ovarian Cancer Day
USA - English España - español | |
| Apr 20, 2021 | BIOVAXYS TECHNOLOGY CORP.
BioVaxys Technology : And The World Ovarian Cancer Coalition Join Forces For May 8th, World Ovarian Cancer Day | VANCOUVER, BC and TORONTO, April 20, 2021 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) ("BioVaxys"), the world leader in haptenized antigen vaccines for antiviral and cancers applications, announced today... |
| Apr 14, 2021 | BioVaxys Announces Final Clinical trial results of HPV product from EU partner ProCare Health Iberia published by American Society for Colposcopy and Cervical Pathology
USA - English USA - English USA - English | |
| Apr 14, 2021 | BIOVAXYS TECHNOLOGY CORP.
BioVaxys Technology : Announces Final Clinical trial results of HPV product from EU partner ProCare Health Iberia published by American Society for Colposcopy and Cervical Pathology | VANCOUVER, BC, April 14, 2021 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA:5LB) (OTC:LMNGF) ("BioVaxys"), the world leader in haptenized antigen vaccines for antiviral and cancers applications, is pleased to announce the re... |
| Mar 31, 2021 | BIOVAXYS files FDA pre-IND meeting request and briefing package for COVID-T | VANCOUVER, BC, March 31, 2021 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA:5LB) (OTC:LMNGF) ("BioVaxys"), the world leader in haptenized antigen vaccines for antiviral and cancer applications, announced today that it is has... |
| Mar 31, 2021 | BIOVAXYS files FDA pre-IND meeting request and briefing package for COVID-T | VANCOUVER, BC, March 31, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA:5LB) (OTC:LMNGF) ("BioVaxys"), the world leader in haptenized antigen vaccines for antiviral and cancer applications, announced today that it... |
| Mar 24, 2021 | BioVaxys Expands Intellectual Property Portfolio
USA - English
España - español | |
| Mar 1, 2021 | BioVaxys Expanding Technology Platform To Address Emerging SARS-CoV-2 Variants | BVX-0320 and Covid-T to have capability to address UK, Brazilian and South African Virus Variants
VANCOUVER, B.C., March 1, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) ("BioVaxys"), the world... |
| Mar 1, 2021 | BioVaxys Expanding Technology Platform To Address Emerging SARS-CoV-2 Variants | VANCOUVER, B.C., March 1, 2021 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) ("BioVaxys"), the world leader in haptenized protein vaccines for antiviral and cancer applications, announced today that it is ... |
| Mar 1, 2021 | BioVaxys Expanding Technology Platform To Address Emerging SARS-CoV-2 Variants | VANCOUVER, B.C., March 1, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) ("BioVaxys"), the world leader in haptenized protein vaccines for antiviral and cancer applications, announced today that... |
| Feb 22, 2021 | BioVaxys Announces Appointment To Its Scientific Advisory Board
USA - English
España - español | |
| Feb 18, 2021 | BioVaxys and BioElpida Sign Term Sheet for Clinical Grade BVX-0918A Bio-production | |
| Feb 16, 2021 | BioVaxys Announces Broadening Of Share Liquidity With DTCC Full Service Eligibility
USA - English
España - español | |
| Feb 12, 2021 | BioVaxys Announces Appointment of Corporate Advisor | |
| Feb 10, 2021 | BioVaxys and Procare Health Announce Broad Co-Development, Joint Commercialization and Marketing Collaboration for Cancer and Viral Vaccines | - USD$900,000 In-Kind Investment by Procare Health into Phase I Clinical Study for BVX-0918A in the EU
- Co-Development of Vaccines for Cervical Cancer and HPV
- Right of First Refusal for US Marketing of Papilocare™
VANCOUVER, BC and BARCE... |
| Feb 10, 2021 | BioVaxys and Procare Health Announce Broad Co-Development, Joint Commercialization and Marketing Collaboration for Cancer and Viral Vaccines | VANCOUVER, BC and BARCELONA, Spain, Feb. 10, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC:L MNGF) ("BioVaxys"), the world leader in haptenized protein vaccines for antiviral and cancer applications, a... |
| Feb 10, 2021 | BioVaxys and Procare Health Announce Broad Co-Development, Joint Commercialization and Marketing Collaboration for Cancer and Viral Vaccines | VANCOUVER, BC and BARCELONA, Spain, Feb. 10, 2021 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC:L MNGF) ("BioVaxys"), the world leader in haptenized protein vaccines for antiviral and cancer applications, and Proc... |
| BioVaxys | “BioVaxys Technology Corp, a leader in biopharmaceutical innovation focused on antiviral and cancer vaccine development. Leveraging our recent acquisition of IMV INC's IP, we're at the forefront of advancing DPX™ delivery technology and hap... |
